<DOC>
	<DOCNO>NCT01461915</DOCNO>
	<brief_summary>The purpose study determine whether ODSH ( 2-0,3-0 desulfated heparin ) , low anticoagulant heparin derivate preserve anti-inflammatory anti-neoplastic characteristic efficacious patient metastatic pancreatic cancer gemcitabine nab-paclitaxel ( Abraxane ) first line therapy .</brief_summary>
	<brief_title>Efficacy &amp; Safety ODSH ( 2-0 , 3-0 Desulfated Heparin ) Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine &amp; Abraxane</brief_title>
	<detailed_description>ODSH demonstrate vitro vivo inhibitory activity mechanism believe play important role pancreatic cancer invasion , metastasis , resistance chemotherapy radiation . Pancreatic cancer appear dependence autophagy , regulate catabolic pathway degrade recycle cellular organelle macromolecule . Autophagy appear largely drive bind high mobility group box-1 protein ( HMGB1 ) receptor advanced glycation end-products ( RAGE ) , strongly inhibit ODSH . Autophagy appear assist pancreatic cancer cell survive hypoxic , relatively avascular environment , also appear play important role chemotherapy resistance . Other important biological activity promote pancreatic cancer invasion metastasis affect ODSH include inhibition heparanase bind tumor cell endothelium platelet mediate selectins . It believe biological activity inhibition RAGE , heparanase , selectin-mediated metastasis , inhibit ODSH dose level safely administer without clinically significant anticoagulation . The standard care pancreatic cancer evolve . It appear two combination regimen , `` FOLFIRINOX '' regimen ( combination 5-fluorouracil , leucovorin , irinotecan oxaliplatin ) combination gemcitabine + nab-paclitaxel , could activity previous standard treatment gemcitabine alone . Subjects advance metastatic pancreatic cancer receive chemotherapy , surgical radiation treatment good performance status eligible participate study . 10 patient enrolled Run-in Period receive gemcitabine + nab-paclitaxel +ODSH . PK sample safety assessment conduct decide continuation Controlled Period study 50 patient randomize 1:1 ratio either two study arm : Arm A receive gemcitabine + nab-paclitaxel + ODSH Arm B receive gemcitabine + nab-paclitaxel . The primary endpoint study mean progression free survival . The secondary endpoint consist tumor response RECIST criterion , overall survival end study change baseline CA19-9 marker , weight plasma albumin .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Patients must histologically confirm adenocarcinoma pancreas metastatic potential curative measure , resection isolate metastasis , available . Patients islet cell neoplasms exclude . 2 . Patient one metastatic tumor measurable CT scan AND serum CA199 measurement &gt; 2 time upper limit normal . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . 3 . Male nonpregnant nonlactating female ≥ 18 ≤ 75 year age . If female patient childbearing potential , must negative serum pregnancy test document within 72 hour prior first administration study drug Day 1 cycle thereafter . If sexually active , patient must agree use contraception prior study entry duration study participation . 4 . Patients must receive prior radiotherapy chemotherapy metastatic disease . Patients receive radiotherapy chemotherapy adjuvant neoadjuvant therapy locally advanced disease six month prior enrollment study eligible . 5 . Patient adequate biological parameter demonstrate follow blood count Screening ( obtain ≤ 14 day prior randomization ) BaselineDay 0 : Absolute neutrophil count ( ANC ) ≥ 1.5 × 109/L ; Platelet count ≥ 100,000/mm3 ( 100 × 109/L ) ; Hemoglobin ( Hgb ) ≥ 9 g/dL . 6 . Patient follow blood chemistry level Screening ( obtain ≤ 14 day prior randomization ) BaselineDay 0 : AST ( SGOT ) , ALT ( SGPT ) ≤ 2.5 × upper limit normal range ( ULN ) , unless liver metastasis present , ≤ 5 × ULN allow . Total bilirubin ≤ 1.5 × ULN . Serum creatinine ( Cr ) within normal limit calculate clearance ≥ 60 mL/min/1.73 m2 patient creatinine ( Cr ) level institutional normal value . If use Cr clearance , actual body weight used calculate Cr clearance ( e.g. , use CockcroftGault formula ) . 7 . Patient acceptable coagulation study Screening ( obtain ≤14 day prior randomization ) demonstrate prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit ( ± 15 % ) . 8 . Patient ECOG performance status ≤ 1 . 1 . Patient brain metastasis . 2 . Patient locally advance disease . 3 . Patient experience increase ECOG &gt; 1 Screening Randomization . 4 . Patient require continuous treatment coumadin oral parenteral anticoagulation ( heparin , LMWH , heparinoids ) prevent treat thromboembolic disease . The use prophylactic antiplatelet drug clopidogrel aspirin allow study . 5 . Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 6 . Patient undergone major surgery , diagnostic surgery ( i.e.surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Randomization study . 7 . Patient history allergy hypersensitivity study drug , pharmaceutical class excipients . 8 . Patient concomitant serious medical psychiatric illness , opinion investigator , could compromise patient 's safety study data integrity . 9 . Patient enrol clinical protocol investigational trial involve administration antineoplastic compound treatment metastatic pancreatic cancer . 10 . Patient unwilling unable comply study procedure . 11 . Nabpaclitaxel metabolize CYP2C8 CYP3A4 . Coadministration substrates , inhibitor CYP2C8 and/or CYP3A4 nabpaclitaxel allow . The following medication substance allow study : ritonavir , saquinavir , indinavir , nelfinavir , rifampicin , carbamazepine , phenytoin , efavirenz , nevirapine , grapefruit ( juice seed ) herbal like St. John 's wort . 12 . Subjects risk factor history Torsades de Pointes ( TdP ) , significant QT prolongation opinion investigator may place study subject risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
</DOC>